Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2020-10-29 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Informacja o podpisaniu umowy z NCBiR o dofinansowanie projektu dotyczącego - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is very short (966 characters) and discusses the signing of a financing agreement (umowy o dofinansowanie) with the National Centre for Research and Development (NCBiR) for a specific project. It references previous current reports (raport bieżący) and details the funding amount (38.9 million PLN) and project timeline. This content relates to receiving funding or a capital update, but it is presented as a brief announcement referencing prior reports, not the full financial report itself. Given the nature of announcing a specific funding agreement and referencing prior reports, it fits best under Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it explicitly details the amount and terms of a significant funding award, CAP is the most precise fit over the general RNS fallback. It is not an announcement of a report publication (RPA) but the substance of a financing event.
2020-10-29 Polish
Trzecie wezwanie akcjonariuszy Celon Pharma S.A. do złożenia dokumentów akcji w Spółce - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document text is a formal notice in Polish from the Management Board of Celon Pharma S.A. ("Emitent") calling upon shareholders to submit their share certificates for dematerialization and registration with the National Securities Depository (KDPW S.A.). This action is mandated by Polish law regarding the dematerialization of shares. The text explicitly mentions this is the third of five required calls to be published as a current report ('raport bieżący'). This process relates directly to changes in the company's capital structure (the conversion of physical shares to electronic form) and is a mandatory regulatory step concerning share ownership. While it touches upon capital structure, the core action is a formal, legally mandated notification process regarding the status of shares. Given the options, 'Share Issue/Capital Change' (SHA) is the closest fit as it deals with the form and registration of shares, although 'Regulatory Filings' (RNS) is a strong secondary candidate if SHA is too specific. Since the document is a direct, legally required announcement about the process of changing the form of shares (dematerialization), SHA is the most precise classification related to capital structure mechanics.
2020-10-21 Polish
Aktualizacja aktywności biznesowych Spółki w zakresie COVID-19 tzn. rozwoju innowacyjnych terapii w obszarze zakażeń SARS-COV-2 oraz rozwoju i wdrożenia diagnostyki SARS-COV-2. - Content (PL)
Management Reports Classification · 95% confidence The document is written in Polish and discusses updates on strategic therapeutic programs for COVID-19, including progress on developing antiviral therapeutics targeting TMPRSS2 protease and RNA polymerase. It mentions previous communications (RB 6/2020, RB 22/2020) and details the positive assessment of project progress, selection of leading compounds, and toxicology studies. It also announces the decision to halt a separate project related to qRT-PCR test manufacturing due to market conditions. This type of detailed, periodic update on R&D progress, strategic shifts, and business environment analysis, often referencing prior regulatory/current reports (RB codes), strongly suggests a Management Discussion and Analysis (MDA) or a detailed Investor Presentation (IP). Given the focus on management's assessment of project progress and strategic decisions (halting the test project), MDA is the most appropriate fit, as it covers management's explanation of business trends and outlook, even if it's not a formal 10-K/IR filing. It is too detailed for a simple ER or RPA.
2020-10-15 Polish
Zmiana terminu publikacji raportu okresowego za III kwartał 2020 roku - Content (PL)
Report Publication Announcement Classification · 98% confidence The document text is very short (345 characters) and explicitly states that the company (Zarząd Celon Pharma S.A.) is informing the public about a *change in the date* for the release of the periodic report for Q3 2020. It announces when the report *will be published* (November 30, 2020), referencing a previous announcement. This structure—announcing the timing or publication of another report—fits the definition of a Report Publication Announcement (RPA). It is not the actual Q3 report (which would be an IR) or a general regulatory filing (RNS), but a specific announcement about the publication schedule.
2020-10-12 Polish
Analiza wyników badania klinicznego II fazy leku opartego na Esketaminie u pacjentów z depresją jednobiegunową w ramach tzw. Follow up - 6 tygodniowej, rozszerzonej obserwacji. - Content (PL)
Legal Proceedings Report Classification · 95% confidence The document text details the completion of analysis for Phase II clinical trial results concerning a drug for unipolar depression. It provides specific efficacy data (MADRS scores, response/remission rates), safety data (adverse events), and pharmacokinetic data (Cmax levels) across different dosage groups and a placebo group. This content is highly specific to clinical trial outcomes and is not a general earnings release (ER), a full annual report (10-K), or a management discussion (MDA). It is a detailed report on clinical study results. Since there is no specific category for 'Clinical Trial Results', I must evaluate the closest fit. It is a detailed report on internal findings, which often accompanies or precedes a formal Audit Report/Information (AR) or could be considered a specialized regulatory filing. Given the detailed nature of the results, it is more substantial than a simple 'Regulatory Filing' (RNS) or 'Report Publication Announcement' (RPA). However, the definitions provided do not explicitly cover clinical trial results. The closest fit among the provided options that deals with internal testing/results is 'Audit Report / Information' (AR), which is defined as 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests'. While this is a clinical trial, it represents the result of an internal test/study. Alternatively, it could be classified as a general 'Regulatory Filing' (RNS) if it's an ad-hoc announcement. Given the depth of the data presented, it functions as a detailed internal report. I will classify it as AR as it represents the results of an internal test/study, which aligns best with the spirit of that definition, although it is not a financial audit. The final sentence mentions details will be presented at upcoming conferences, suggesting this is the initial release of the findings.
2020-10-12 Polish
Zarekomendowanie przez NCBR do dofinansowania projektu rozwoju CPL’116 w leczeniu idiopatycznego zwłóknienia płuc w wysokości 18,7 mln. - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement from the Management Board ('Zarząd') of Celon Pharma S.A. regarding the recommendation for funding (dofinansowanie) by the National Centre for Research and Development (NCBR) for a specific drug development project (CPL409116). This announcement details the project scope, costs (approx. 36.4 million PLN), requested funding (18.7 million PLN), and the therapeutic area (Idiopathic Pulmonary Fibrosis - IPF). This clearly relates to the company's financing activities, specifically securing a grant or subsidy for R&D, which falls under Capital/Financing Updates. The final sentence, 'O zawarciu umowy o dofinansowanie Spółka poinformuje odrębnym raportem bieżącym' (The Company will inform about the conclusion of the co-financing agreement in a separate current report), confirms this is an announcement about a financing event, not the final contract or a full financial report. Therefore, the appropriate code is CAP.
2020-10-06 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.